I will affirm i760's comments. It's too early to tell. ORIC hasn't helped us. When the company does its public facing presentations and scientific articles, it compares its drug to Korlym (mfiepristone), not to any other Corcept drug.
That's no help.
I have consulted someone regarding the differences in the structure of relacorilant versus Oric's drug. There are some guesses but that's truly next to worthless.
The cows don't come home until we see the results.
To Corcept's credit, they're testing three different drugs in prostate cancer: Korlym, Relacorilant, and CORT125281.
Believe it or not, if all things are equal, I'd like to see CORT125281 advanced to approval. It provides an additional "backup drug" to relacorilant and maybe even imparts additional flexibility around out-licensing.
Of course, things are rarely equal.